Recruiting
Early Phase 1

Upadacitinib

Sponsor:

Northwestern University

Code:

NCT06684522

Conditions

Eyelid Dermatitis

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Upadacitinib 15 MG

Study Details

Brief summary:

This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.

Conditions

Eyelid Dermatitis

Study ID

NCT06684522

Start date

Dec 18, 2025

Status verified date

May, 2026

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Individuals age 18-70 years old with eyelid dermatitis for at least two months
  • Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib)
  • Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib.
  • Willing and able participants that provide informed consent
  • Willing and able participants that comply with study activities

Exclusion Criteria:

  • Self-reported history of allergic response to upadacitinib
  • Subject with self-reported history of heart disease, stroke, or neurological conditions
  • Currently taking topical medications for eyelid dermatitis within one week of starting study drug
  • Women who are pregnant, nursing, or who may become pregnant during the study
  • Non-English-speaking subjects
  • Patients with an active serious infection
  • Patients with active TB or latent TB, patients should be tested for TB prior to upadacitinib treatment.
  • Patients with active HBV/HCV or abnormal lab ranges, Lab Data: Hb<8g/dL, ALC<500 cells/mm3 and ANC <1000 cells/mm3
  • Patients with a history of malignancy within the last 5 years other than successfully treated NMSC.

Study Design

Enrollment

10 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Upadacitinib Treatment

Participants on upadacitinib 15mg daily

Interventions

Upadacitinib 15 MG

Upadacitinib 15mg daily

Primary outcome measure

  • Reduction in Investigator Global Assessment (IGA) [ Time Frame: 12 weeks ]

Central Contacts and Locations

Central contacts

Dermatology CTU

312-503-5944NUderm-research@northwestern.edu

Locations

Northwestern University Department of Dermatology

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Dermatology CTU

NUderm-research@northwestern.edu

More Information

Sponsor

Northwestern University

Last update posted

May 26, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Northwestern University on 2026-05-26.